We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

93 hedge funds and large institutions have $66.5M invested in Relmada Therapeutics in 2024 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 21 increasing their positions, 26 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 9

51% more call options, than puts

Call options by funds: $907K | Put options by funds: $602K

17% more capital invested

Capital invested by funds: $56.7M → $66.5M (+$9.79M)

12% more funds holding

Funds holding: 83 → 93 (+10)

1.89% more ownership

Funds ownership: 45.55% → 47.44% (+1.9%)

19% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 26

Holders
93
Holders Change
+10
Holders Change %
+12.05%
% of All Funds
1.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
21
Reduced
26
Closed
9
Calls
$907K
Puts
$602K
Net Calls
+$305K
Net Calls Change
+$1.42M

Top Buyers

Rank Fund Capital Flow
1
VPC
Vestal Point Capital
New York
+$5.23M
2
Franklin Resources
Franklin Resources
California
+$3.04M
3
Jane Street
Jane Street
New York
+$786K
4
JP Morgan Chase
JP Morgan Chase
New York
+$757K
5
Millennium Management
Millennium Management
New York
+$687K

Top Sellers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
-$3.88M
2
Citadel Advisors
Citadel Advisors
Florida
-$1.47M
3
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
-$1.12M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.03M
5
OM
Opaleye Management
Massachusetts
-$569K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
26
Citigroup
New York
$576K +$244K +50,690 +69%
Morgan Stanley
27
Morgan Stanley
New York
$560K -$288K -59,706 -33%
Goldman Sachs
28
Goldman Sachs
New York
$550K +$570K +118,243 New
State Street
29
State Street
Massachusetts
$517K -$19.8K -4,100 -4%
GCP
30
GSA Capital Partners
United Kingdom
$480K -$392K -81,252 -44%
MOS
31
MGO One Seven
Ohio
$465K – – –
SCM
32
Silverarc Capital Management
Massachusetts
$462K -$2.99K -621 -0.6%
Federated Hermes
33
Federated Hermes
Pennsylvania
$446K -$18.5K -3,829 -4%
Fidelity Investments
34
Fidelity Investments
Massachusetts
$390K -$1.45K -301 -0.4%
Northern Trust
35
Northern Trust
Illinois
$377K -$73.3K -15,218 -16%
Squarepoint
36
Squarepoint
New York
$367K +$26.9K +5,579 +8%
AW
37
Apricus Wealth
South Carolina
$367K – – –
CF
38
Cantor Fitzgerald
New York
$357K +$354K +73,500 New
Dimensional Fund Advisors
39
Dimensional Fund Advisors
Texas
$343K – – –
Qube Research & Technologies (QRT)
40
Qube Research & Technologies (QRT)
United Kingdom
$339K +$328K +68,005 +1,367%
Man Group
41
Man Group
United Kingdom
$336K +$348K +72,318 New
Citadel Advisors
42
Citadel Advisors
Florida
$328K -$1.47M -305,114 -81%
AI
43
AdvisorShares Investments
Maryland
$326K -$22.2K -4,613 -6%
CSS
44
Cubist Systematic Strategies
Connecticut
$238K +$247K +51,161 New
PAS
45
Point72 Asia (Singapore)
Singapore
$232K +$240K +49,882 New
Simplex Trading
46
Simplex Trading
Illinois
$217K -$44.7K -9,272 -17%
JF
47
Jump Financial
Illinois
$210K +$218K +45,249 New
IC
48
Ikarian Capital
Texas
$188K – – –
SEI Investments
49
SEI Investments
Pennsylvania
$169K – – –
Renaissance Technologies
50
Renaissance Technologies
New York
$163K -$539K -111,881 -76%
1
2
3 4 5

RLMD Hedge Fund Activity: Q1 2024 in Review

93 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q1 2024, worth a combined $66.5M — up 17% from $56.7M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new RLMD positions and 9 closed out — a net gain of 10 holders — while 21 added to existing stakes and 26 trimmed.

The largest buyer was Vestal Point Capital, adding an estimated $5.23M. The largest seller was Deep Track Capital, cutting an estimated $3.88M.

  • 93 institutional investors held Relmada Therapeutics (RLMD) as of Q1 2024, up from 83 in Q4 2023.
  • Funds reported $66.5M of Relmada Therapeutics stock for Q1 2024, up 17% quarter-over-quarter.
  • 19 funds opened new Relmada Therapeutics positions in Q1 2024 and 9 closed out, a net change of +10 holders.
  • The largest Relmada Therapeutics buyer in Q1 2024 was Vestal Point Capital, an estimated $5.23M added.
  • The largest Relmada Therapeutics seller in Q1 2024 was Deep Track Capital, an estimated $3.88M sold.

Based on aggregated 13F filings for Q1 2024.